Photodynamic occlusion of ocular neo-vascularization with B2 vitamin.
Photodynamic therapy (PDT) of cancer has been known for over twenty years and is based on the dye-sensitized photooxidation of different biological targets in the tumoral tissue yielding to a photochemically induced cell's death via apoptotic pathways. Several parameters affect clinical trials in PDT and influence the therapeutic outcome. A potentially major application of PDT in a non-cancer field is its use in treatment of age-related macular degeneration. This condition, caused by proliferation of neovasculature in the retina, is the major cause of blindness in the over 50s. Using a photosensitiser which enters neovasculature very rapidly following administration and is subsequently quickly moved from the circulation. Ocular neovascular disease represents an important cause of blindness today. In this paper, was used an animal model (rabbit) to evaluate the vaso-occlusive potential of photodynamic therapy with B2 vitamin. Neovascularization induced in the rabbit cornea consists of an easily accessible monolayer-like neovascular net within a transparent matrix. This fact allows studying the efficiency of occlusion in an isolated neovascular structure.
Institute for Chemical Research, Icechim, Chemical Analysis Department, Splaiul Independenţeii 202, Bucharest-79611, Romania. irma@pcnet.ro
M A
MA
Ioniţă
R M
RM
Ion
B
B
Cârstocea
O L
OL
Gafencu
V I R
VI
Niculescu
D000818:Animals; D004195:Disease Models, Animal; D005583:Fourier Analysis; D006801:Humans; D008268:Macular Degeneration / Q000517:prevention & control; D010778:Photochemotherapy / Q000379:methods; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011817:Rabbits; D015861:Retinal Neovascularization / Q000188:drug therapy*; D012256:Riboflavin / Q000627:therapeutic use*; D016896:Treatment Outcome
D017319:Photosensitizing Agents; D012256:Riboflavin